Volume 58, Issue 1, Pages (July 2010)

Slides:



Advertisements
Similar presentations
Between-Method Differences in Prostate Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms C. Stephan, K. Siemβen, H. Cammann,
Advertisements

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Volume 56, Issue 5, Pages (November 2009)
Volume 72, Issue 1, Pages (July 2017)
Volume 155, Issue 3, Pages (March 1996)
Volume 50, Issue 3, Pages (September 2006)
The PSA Era is not Over for Prostate Cancer
Volume 68, Issue 6, Pages (December 2015)
Volume 50, Issue 1, Pages (July 2006)
Volume 52, Issue 1, Pages (July 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 52, Issue 5, Pages (November 2007)
Prostate Cancer 2008: Challenges in Diagnosis and Management
Volume 52, Issue 1, Pages (July 2007)
Prostate Cancer: Highlights from 2006
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 42, Issue 4, Pages (October 2002)
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
Volume 61, Issue 3, Pages (March 2012)
Volume 63, Issue 4, Pages (April 2013)
Volume 59, Issue 2, Pages (February 2011)
Bladder Cancer: A Major Public Health Issue
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 60, Issue 5, Pages (November 2011)
Towards Early and More Specific Diagnosis of Prostate Cancer
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Volume 68, Issue 3, Pages (September 2015)
Volume 56, Issue 2, Pages (August 2009)
Volume 67, Issue 4, Pages (April 2015)
Volume 73, Issue 4, Pages (April 2018)
Volume 63, Issue 6, Pages (June 2013)
Volume 54, Issue 2, Pages (August 2008)
Volume 185, Issue 2, Pages (February 2011)
Luis Martínez-Piñeiro  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 66, Issue 5, Pages (November 2014)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 54, Issue 3, Pages (September 2008)
Volume 58, Issue 1, Pages 1-7 (July 2010)
Volume 65, Issue 6, Pages (June 2014)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 65, Issue 1, Pages (January 2014)
Volume 50, Issue 5, Pages (November 2006)
Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer  MICHAEL R. CUPP,
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 70, Issue 2, Pages (August 2016)
Prostate Cancer Nomograms: An Update
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 72, Issue 1, Pages (July 2017)
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Volume 74, Issue 6, Pages (December 2018)
Apoorva R. Vashi, M.D., Joseph E. Oesterling, M.D. 
Prostate Cancer 2008: Challenges in Diagnosis and Management
Volume 54, Issue 5, Pages (November 2008)
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
Management of Prostate Cancer: Global Strategies
Volume 50, Issue 6, Pages (December 2006)
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Volume 74, Issue 6, Pages (December 2018)
Volume 54, Issue 3, Pages (September 2008)
Volume 52, Issue 5, Pages (November 2007)
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

Volume 58, Issue 1, Pages 12-18 (July 2010) Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours  Florian Jentzmik, Carsten Stephan, Kurt Miller, Mark Schrader, Andreas Erbersdobler, Glen Kristiansen, Michael Lein, Klaus Jung  European Urology  Volume 58, Issue 1, Pages 12-18 (July 2010) DOI: 10.1016/j.eururo.2010.01.035 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Sarcosine-creatinine ratio in urine of patients with prostate cancer (PCa) and with no evidence of malignancy (NEM) after digital rectal examination and in healthy females (HF) and males (HM). (A) Sarcosine in urine of the study groups. Differences between the NEM and PCa patients and between healthy females and males were tested by the Mann-Whitney U-test. (B) Sarcosine in urine of the PCa patients categorised according to the pathologic tumour stage pT2 and pT3. (C) Sarcosine in urine of the PCa patients categorised according to the biopsy-based Gleason scores <7 and ≥7. (D) Sarcosine in urine of the PCa patients categorised according to the prostatectomy-based Gleason scores <7 and ≥7. Differences between (B those categorised according to the pathologic tumour stage pT2 and pT3 and (C) those categorised according to the biopsy-based Gleason scores <7 and ≥7 were tested by the Mann-Whitney U test. European Urology 2010 58, 12-18DOI: (10.1016/j.eururo.2010.01.035) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Sarcosine-creatinine ratio in urine of patients with prostate cancer (PCa) and with no evidence of malignancy (NEM) after digital rectal examination in relation to (A) age, (B) serum prostate-specific antigen, (C) prostate volume, and (D) creatinine in urine. The Spearman rank correlation coefficients (rS) and the linear regression lines were separately calculated for NEM (blue circle and line) and PCa (orange circle and line) patients. Since there were no significant differences between NEM and PCa patients, only the combined rS for both groups is indicated. European Urology 2010 58, 12-18DOI: (10.1016/j.eururo.2010.01.035) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Sarcosine-creatinine ratio in urine before and after digital rectal examination of prostate cancer patients. Urine samples of 10 patients were measured before and after the standardised digital rectal examination procedure according to Deras et al. [11]. Differences were tested by the Wilcoxon matched-pairs test. European Urology 2010 58, 12-18DOI: (10.1016/j.eururo.2010.01.035) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Receiver operating characteristic curves for sarcosine in urine, total prostate-specific antigen (PSA), and percent ratio of free to total PSA (%fPSA) to differentiate between prostate cancer (PCa) patients and patients with no evidence of malignancy (NEM). (A) Patients with PSA concentrations <20 ng/ml (PCa, n=106; NEM, n=33) and (B) with PSA concentrations <10 ng/ml (PCa, n=71; NEM, n=28) were tested. Area under the curve (AUC) of %fPSA was significantly larger than that of sarcosine (p=0.012) and clearly different from that of the null hypothesis value of 0.5 (p<0.0001). The AUCs of PSA were not different from that of sarcosine (p=0.933 and p=0.370, respectively). European Urology 2010 58, 12-18DOI: (10.1016/j.eururo.2010.01.035) Copyright © 2010 European Association of Urology Terms and Conditions